LHRH-R is also significantly upregulated in ~50% of hormone-dependent breast cancers [7, 8], ~86% of prostate cancers [9–11], ~80% of endometrial cancers [12, 13], and ~90% of ovarian cancers, [12, 14] where it is similarly believed to promote cell proliferation and survival. Here, GNRHR is linked to endometrial cancer.